Notice Number: NOT-OD-16-077
Key Dates
Release Date: March 15, 2016
PAR-16-106
Issued by
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
Purpose
The purpose of this Notice is to inform potential applicants that the Office of Research Infrastructure Programs (ORIP) is participating, effective immediately, in PAR-16-106 "Rapid Assessment of Zika Virus (ZIKV) Complications (R21)."
The following sections of PAR-16-106 have been updated to reflect ORIP participation in this Funding Opportunity Announcement (FOA):
Part 1. Overview Information
Components of Participating Organizations
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Neurological Disorders and Stroke (NINDS)
National Eye Institute (NEI)
National Institute of Biomedical Imaging (NIBIB)
National Heart, Lung, and Blood Institute (NHLBI)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.865, 93.286; 93.856; 93.855; 93.867; 93.853; 93.121; 93.839, 93.351
Part 2. Section I. Funding Opportunity Description
Research Scope
ORIP
The Office of Research Infrastructure Programs (ORIP) in the Office of the NIH Director (OD) has a particular interest in developing and characterizing animal models that can be used to study basic aspects of ZIKV infection and pathogenesis and can be correlated with infection in humans. ORIP recognizes that no single animal model may accurately reflect all aspects of infection in humans. Models that can be used to analyze specific aspects of pathogenesis and/or infection are acceptable.
Areas of high priority to ORIP include, but are not limited to, development of animal models in which the following can be accessed:
For adult males and pregnant and/or non-pregnant females:
- Kinetics of infection, including levels of viremia, resolution of plasma viremia, and presence of virus in tissues and body fluids such as saliva, vaginal secretions, breast milk, urine and semen.
- Persistence of virus in animal compartments after resolution of plasma viremia.
- Correlates of infection, including, among others, innate and adaptive immune responses, both humoral and cellular.
- For nonhuman primates, development and comparison of models in both new world and old world species.
- Differences in infection dependent on the mode of transmission, e.g. by mosquito bite or by direct injection into the blood stream or other tissue compartments.
- Transfer of virus between males and females by sexual intercourse.
- Relationship of ZIKV infection to prior or co-infection with other viruses, particularly other flaviviruses such as dengue virus.
For fetuses, neonates and infants:
- Methods by which ZIKV can be introduced directly into the fetus, e.g., by injection into the placenta or into the fetus itself.
- Infection from the mother during gestation and/or from breast milk.
- Presence of ZIKV in the brain and nervous system following infection.
- Effects of infection on microcephaly and behavior.
Part 2. Section VII. Agency Contacts
Scientific/Research Contact(s)
Stephanie Murphy, V.M.D., Ph.D.
Office of Research Infrastructure ProgramsTelephone: 301-451-7818
Email: [email protected]
Financial/Grants Management Contact(s)
Kristin WegnerOffice of Research Infrastructure Programs, OD, NIH
Telephone: 301-435-0848
Email: [email protected]
No other changes are made to this FOA.
Inquiries
Please direct all inquiries to:
Stephanie Murphy, V.M.D., Ph.D.
Office of Research Infrastructure Programs (ORIP)
Telephone: 301-451-7818
Email: [email protected]
and Human Services (HHS)
